The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Hey bennitto,
Not a replacement for corticosteroids as they help for example asthmatics manager their condition on a day to day basis.
The problems start when they have other additional problems causing severe breathlessness some of which have drugs
that can help:
Allergic reaction = antihistamine
Bacterial infection = Antibiotics
Fungal infection (Aspergillosis) = Antifungal
Severe viral infection ? Antiviral = SNG001 (Prof SH " We know it works")
No question a successful P3 will then lead to further investigation for the beneficial use of SNG001.
GLA Ranger
With the info so available you are extremely poorly researched, a pointless poster
or a lying....... 123 in you go!
Naewise, this has been well covered on here.
Not a treatment for Asthma but an agnostic
antiviral to treat viral infections which in Asthma
sufferers can & often do cause severe exacerbations
leading to breathlessness, hospitalisation and death.
I am sure if the RNS we are waiting for is as good as we
all believe then you will see Synairgen finish their work on
COPD, Asthma.
Hang in there everyone not long now!
Our Strategy
We are focused on developing our product candidate, ensifentrine, which we believe has the potential to become an important and novel treatment for chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other respiratory diseases, including asthma. We own the global development and commercialization rights to ensifentrine.
Advance nebulized ensifentrine in Phase 3 trials for COPD
Nebulized ensifentrine is in Phase 3 clinical trials as a maintenance treatment for COPD. Millions of COPD patients urgently need better treatments as they remain symptomatic despite maximum treatment with currently available therapies. In the US alone, total annual medical costs, indirect and direct, relating to COPD are projected to rise to about $50 billion in 2020. We believe ensifentrine will have an important role as an add-on therapy for dual/triple treated patients.
Develop formulations of ensifentrine for handheld inhalers
In addition to nebulized ensifentrine, we have developed dry powder inhaler (DPI) and pressurized metered dose inhaler (pMDI) formulations of ensifentrine for less severe patients. Initial results from Phase 2 trials for the maintenance treatment of COPD are promising. In the US, DPI and pMDI handheld inhalers are the most widely used option for medication in COPD, with an estimated 5.5 million people using them for COPD maintenance therapy. This market was valued at approximately $10 billion in 2019.
Seek strategic relationships
We may seek strategic collaborations with leading biopharmaceutical companies to develop and commercialize ensifentrine. These partnerships could provide significant funding to advance the development of ensifentrine while allowing us to benefit from the development and commercialization expertise of our collaborators.
Develop ensifentrine for cystic fibrosis and severe asthma
We may develop ensifentrine for cystic fibrosis and severe asthma. CF is considered an orphan disease by both the US and European regulatory authorities. According to WHO estimates, 300 million people suffer from asthma and it is the most common chronic disease amongst children.
Pursue development of ensifentrine in additional territories
Initially, we are developing ensifentrine for the US and European markets. We have formed a $219 million strategic collaboration with Nuance Pharma to develop and commercialize ensifentrine in Greater China. The region has more than 50 million COPD patients and is estimated to grow to 70 million in 2030.
Acquire or in-license product candidates for respiratory diseases
We are leveraging our expertise in respiratory diseases to in-license or acquire additional clinical-stage product candidates. We are seeking assets with the potential to become novel treatments for respiratory diseases with significant unmet medical needs.
Interesting.....?
Spot on Axe did it a while back, just too much sh.t.
Hey Doc, I see Tweedleandyb & Tweedlendn are at it again.
I can vouch for the benefits of a Jan green box cull.
I concluded Mon 31st Jan Parody Parrot but agree that 10 days up to 9th Feb
felt right to me pure gut instinct though.
Kev I think that's the 401K pension provision/contribution.
That is really good news Helen!
Reading this just highlights what a breakthrough SNG001 could be
in the treatment of Covid 19. So many narrow treatment pathways,
lots of may, could, suggest & more study. You can see why 3 billion
being thrown at antiviral treatment in USA.
https://www.health.harvard.edu/diseases-and-conditions/treatments-for-covid-19
HeleB, I am so sorry to hear this at a time we are so hopeful & excited
about a positive outcome for SNG001.
As a chronic life long 59 yr asthmatic I would say do what you normally do
with a bad viral infection. I would consider using a spacer for your son to take his
inhalers, something he might not have done since he was younger. I would increase
to the higher doses of whichever inhaled drugs he normally takes; don't wait for
breathlessness. Contact your GP see if there is another treatment that he could try
for instance for me Symbicort 200 worked much better as a treatment almost
eliminating the need for ventolin (Salbutamol) as a reliever and dosage can be increased
considerably if needed. Light precussive manipulation/ impact/massage on the back & chest can help
keep that area relaxed & makes it easier to clear the lungs. The apple cider vinegar & honey
can help but as part of a regular hot drink & paracetemol regimen. Lots & lots of fresh air with room temperature
warm but not hot. Talk to the GPs asthma nurse to see if she has picked up any useful tips treating
other asthma patients suffering with Covid 19.
You may be doing all this & more of course.
The best thing he has is a Mum like you in his corner.
Good luck and all the very best Ranger.
Oh dear Manc we have come to expect more effort from those special
people providing our weekend entertainment! LOL
https://www.msn.com/en-gb/health/familyhealth/children-with-bad-asthma-should-be-offered-covid-jab-study-finds/ar-AARjRDh?li=AAJt1k3
HeleB, I totally agree that is a group of people that need SNG001 not just for Covid but for the many respiratory virus that they
have to contend with now & in the future. They will be foremost in Prof Sir SH & teams mind at this time of year & were probably the group that inspired them to begin work so many years ago. I think by winter 2023 they will have the safety net of
SNG001 a true agnostic antiviral. All the best holders, Ranger.
https://www.ii.co.uk/analysis-commentary/top-25-most-traded-companies-aim-ii522134
Synairgen in this list no surprise to LTH of course
We need to do a re-think on antivirals....
Tim45
So dry I needed a coffee after reading it. :)
Cannot get a live price for a small buy on ii estimate 2.14.
https://pharmaceutical-journal.com/article/feature/everything-you-need-to-know-about-the-covid-19-therapy-trials
Apologies if this is already covered but looks like an update 22/10/2021.
Interferons
Modulate immune response to some viral infections;
Only limited clinical trial data are currently available on the efficacy of IFNs for treatment of COVID-19;
Clinical trials are currently evaluating IFN beta-1a or IFN beta-1b, generally added to antivirals.
Evidence
Interferon beta-1a plus remdesivir was not superior to remdesivir alone in hospitalised patients with COVID-19 pneumonia. Patients who required high-flow oxygen at baseline had worse outcomes after treatment with interferon beta-1a compared with those given placebo (Kalil et al, 18 October 2021);
Interim results from the Solidarity trial suggest that IFN beta-1a has little or no effect on mortality in patients who are hospitalised with COVID-19 (15 October 2020).
Results of a small randomised, double-blind, placebo-controlled, phase II pilot trial of inhaled nebulised interferon beta-1a (SNG001) in adults admitted to hospital with COVID-19 suggest a greater odds of improvement on the WHO Ordinal Scale for Clinical Improvement (OSCI) (odds ratio 2·32 [95% CI 1·07–5·04]) on day 15 or 16 versus placebo. and were more likely than those receiving placebo to recover to an OSCI score of 1 (no limitation of activities) during treatment (hazard ratio 2·19 [95% CI 1·03–4·69]). (Monk et al, 12 November 2020).
Ongoing trials
REMAP-CAP;
Comparing efficacy and safety of inhaled SNG001 to placebo;
SOLIDARITY;
DISCOVERY;
RECOVERY.
Yes last year but just wanted to change the subject.